



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent  
Licensee of the Blue Cross and Blue Shield Association

## Medical Policy

### Esophageal pH Monitoring

#### Table of Contents

- [Policy: Commercial](#)
- [Coding Information](#)
- [Information Pertaining to All Policies](#)
- [Policy: Medicare](#)
- [Description](#)
- [References](#)
- [Authorization Information](#)
- [Policy History](#)

#### Policy Number: 069

BCBSA Reference Number: 2.01.20 (For Plans internal use only)

NCD/LCD: N/A

#### Related Policies

None

#### Policy

#### Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

Esophageal pH monitoring using a wireless or catheter-based system may be considered **MEDICALLY NECESSARY** for the following clinical indications in adults and children or adolescents able to report symptoms\*:

- Documentation of abnormal acid exposure in endoscopy-negative patients being considered for surgical anti-reflux repair,
- Evaluation of patients after anti-reflux surgery who are suspected of having ongoing abnormal reflux,
- Evaluation of patients with either normal or equivocal endoscopic findings and reflux symptoms that are refractory to proton pump inhibitor therapy,
- Evaluation of refractory reflux in patients with chest pain after cardiac evaluation and after a 1-month trial of proton pump inhibitor therapy,
- Evaluation of suspected otolaryngologic manifestations of GERD (i.e., laryngitis, pharyngitis, chronic cough) that have failed to respond to at least 4 weeks of proton pump inhibitor therapy, or
- Evaluation of concomitant GERD in an adult-onset, non-allergic asthmatic suspected of having reflux-induced asthma.

24-hour catheter-based esophageal pH monitoring may be **MEDICALLY NECESSARY** in infants or children who are unable to report or describe symptoms of reflux with:

- Unexplained apnea,
- Bradycardia,
- Refractory coughing or wheezing, stridor, or recurrent choking (aspiration),
- Persistent or recurrent laryngitis,
- Recurrent pneumonia.

Catheter-based impedance-pH monitoring is **NOT MEDICALLY NECESSARY**.

\*Esophageal pH monitoring systems should be used in accordance with FDA-approved indications and age ranges.

## Prior Authorization Information

### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

### Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is <b>not required</b> .
Commercial PPO and Indemnity	Prior authorization is <b>not required</b> .
Medicare HMO Blue <sup>SM</sup>	Prior authorization is <b>not required</b> .
Medicare PPO Blue <sup>SM</sup>	Prior authorization is <b>not required</b> .

## CPT Codes / HCPCS Codes / ICD Codes

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

*The following codes are included below for informational purposes only; this is not an all-inclusive list.*

The above **medical necessity criteria MUST** be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

### CPT Codes

CPT codes:	Code Description
91034	Esophagus, gastroesophageal reflux test; with nasal catheter pH electrode(s) placement, recording, analysis and interpretation
91035	Esophagus, gastroesophageal reflux test; with mucosal attached telemetry pH electrode placement, recording, analysis and interpretation

The following ICD Diagnosis Codes are considered medically necessary when submitted with the CPT codes above if **medical necessity criteria** are met

### ICD-10 Diagnosis Codes

ICD-10-CM Diagnosis codes:	Code Description
G47.30	Sleep apnea, unspecified
J37.0	Chronic laryngitis
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation
J44.9	Chronic obstructive pulmonary disease, unspecified
J45.20	Mild intermittent asthma, uncomplicated

J45.21	Mild intermittent asthma with (acute) exacerbation
J45.22	Mild intermittent asthma with status asthmaticus
J45.30	Mild persistent asthma, uncomplicated
J45.31	Mild persistent asthma with (acute) exacerbation
J45.32	Mild persistent asthma with status asthmaticus
J45.40	Moderate persistent asthma, uncomplicated
J45.41	Moderate persistent asthma with (acute) exacerbation
J45.42	Moderate persistent asthma with status asthmaticus
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation
J45.52	Severe persistent asthma with status asthmaticus
J45.991	Cough variant asthma
K21.00	Gastro-esophageal reflux disease with esophagitis, without bleeding
K21.01	Gastro-esophageal reflux disease with esophagitis, with bleeding
K21.9	Gastro-esophageal reflux disease without esophagitis
P22.8	Other respiratory distress of newborn
P22.9	Respiratory distress of newborn, unspecified
P24.30	Neonatal aspiration of milk and regurgitated food without respiratory symptoms
P24.31	Neonatal aspiration of milk and regurgitated food with respiratory symptoms
P24.81	Other neonatal aspiration with respiratory symptoms
P28.2	Cyanotic attacks of newborn
P28.30	Primary sleep apnea of newborn, unspecified
P28.31	Primary central sleep apnea of newborn
P28.32	Primary obstructive sleep apnea of newborn
P28.33	Primary mixed sleep apnea of newborn
P28.39	Other primary sleep apnea of newborn
P28.40	Unspecified apnea of newborn
P28.41	Central neonatal apnea of newborn
P28.42	Obstructive apnea of newborn
P28.43	Mixed neonatal apnea of newborn
P28.49	Other apnea of newborn
P28.5	Respiratory failure of newborn
P28.81	Respiratory arrest of newborn
P28.89	Other specified respiratory conditions of newborn
P29.12	Neonatal bradycardia
P84	Other problems with newborn
R05.3	Chronic cough
R05.4	Cough syncope
R05.8	Other specified cough
R05.9	Cough, unspecified
R06.1	Stridor
R06.2	Wheezing
R06.81	Apnea, not elsewhere classified
Z87.01	Personal history of pneumonia (recurrent)

The following CPT codes are considered investigational for **Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

### CPT Codes

CPT codes:	Code Description
------------	------------------

91037	Esophageal function test, gastroesophageal reflux test with nasal catheter intraluminal impedance electrode(s) placement, recording, analysis and interpretation;
91038	Esophageal function test, gastroesophageal reflux test with nasal catheter intraluminal impedance electrode(s) placement, recording, analysis and interpretation; prolonged (greater than 1 hour, up to 24 hours)

## Description

### Gastroesophageal Reflux Disease

Acid reflux is the cause of heartburn and acid regurgitation esophagitis, which can lead to esophageal stricture. Acid reflux can also cause or contribute to some cases of asthma, posterior laryngitis, chronic cough, dental erosions, chronic hoarseness, pharyngitis, subglottic stenosis or stricture, nocturnal choking, and recurrent pneumonia.

### Diagnosis

Gastroesophageal reflux disease is most commonly diagnosed by clinical evaluation and treated empirically with a trial of medical management. For patients who do not respond appropriately to medications, or who have recurrent chronic symptoms, endoscopy is indicated to confirm the diagnosis and assess the severity of reflux esophagitis. In some patients, endoscopy is nondiagnostic, or results are discordant with the clinical evaluation (in these cases, further diagnostic testing may be of benefit).

### Monitoring

Esophageal monitoring is done using a tube with a pH electrode attached to its tip, which is then passed into the esophagus to approximately 5 cm above the upper margin of the lower esophageal sphincter. The electrode is attached to a data recorder worn on a waist belt or shoulder strap. Every instance of acid reflux, as well as its duration and pH, is recorded over a 24-hour period. Wireless pH monitoring is achieved using endoscopic or manometric guidance to attach the pH measuring capsule to the esophageal mucosa using a clip. The capsule records pH levels for up to 96 hours and transmits them via radiofrequency telemetry to a receiver worn on the patient's belt. Data from the recorder are uploaded to a computer for analysis by a nurse or doctor.

Another technology closely related to pH monitoring is impedance pH monitoring, which incorporates pH monitoring with measurements of impedance, a method of measuring reflux of liquid or gas of any pH. Multiple electrodes are placed along the length of the esophageal catheter. The impedance pattern detected can determine the direction of flow and the substance (liquid or gas). Impedance monitoring can identify reflux events in which the liquid is only slightly acidic or nonacidic.

## Summary

Esophageal pH monitoring, using wired or wireless devices, can record the pH of the lower esophagus for a period of several days. Impedance pH monitoring measures electrical impedance in the esophagus to evaluate reflux episodes concurrent with changes in pH. These tests are used for certain clinical indications in the evaluation of gastroesophageal reflux disease (GERD).

For individuals who have GERD who receive catheter-based pH monitoring, the evidence includes cross-sectional studies evaluating test performance in different populations. Relevant outcomes are test validity, symptoms, and functional outcomes. Positive pH monitoring tests correlate with endoscopically defined GERD and with GERD symptoms, but because there is no reference standard for clinical GERD, diagnostic characteristics cannot be determined. There are no studies of clinical utility showing improved outcomes, and the chain of evidence supporting the utility of the test is weak. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have GERD who receive wireless pH monitoring, the evidence includes a systematic review and cross-sectional studies evaluating test performance and diagnostic yield in different populations. Relevant outcomes are test validity, symptoms, and functional outcomes. Positive wireless pH monitoring tests correlate with endoscopically defined GERD and GERD symptoms, but because there is no reference standard for clinical GERD, diagnostic characteristics cannot be determined. Some

studies have shown higher positive test rates with prolonged wireless monitoring compared with catheter-based pH monitoring, but the effect of this finding on patient outcomes is uncertain. There are no studies of clinical utility showing improved outcomes, and the chain of evidence supporting the utility of the test is weak. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have GERD who receive impedance pH testing, the evidence includes cross-sectional studies evaluating test performance and diagnostic yield in different populations. Relevant outcomes are test validity, symptoms, and functional outcomes. Positive impedance pH tests correlate with endoscopically defined GERD and with GERD symptoms, but because there is no reference standard for clinical GERD, diagnostic characteristics cannot be determined. Some studies have shown higher positive test rates with impedance pH testing compared with pH testing alone, but the effect of this finding on patient outcomes is uncertain. There are no studies of clinical utility showing improved outcomes, and the chain of evidence supporting the utility of the test is weak. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## Policy History

Date	Action
10/2022	Clarified coding information.
1/2022	Annual review. Description, summary, and references updated. Policy statements unchanged.
10/2021	Clarified coding information
1/2021	Annual review. Description, summary, and references updated. Policy statements unchanged.
10/2020	Clarified coding information
1/2020	Annual review. Description, summary, and references updated. Policy statements unchanged.
1/2019	Annual review. Description, summary, and references updated. Policy statements unchanged.
1/2018	Annual review. New references added.
10/2015	Clarified coding information.
12/2014	Clarified coding information.
9/2014	Annual review. New references added.
5/2014	Updated Coding section with ICD10 procedure and diagnosis codes. Effective 10/2015.
4/2014	Clarified coding information.
12/2013	Annual review. Removed "24-hour" from the policy statement on impedance monitoring; catheter-based impedance monitoring for any length of time is considered not medically necessary. Effective 12/1/2013. Removed ICD-9 diagnosis codes 427.89, 462; 464.00; 464.01; 486; 493.00; 493.01; 493.02; 493.81; 493.90; 493.91; 493.92 as these do not meet the intent of the policy. ICD-9 diagnosis code V12.61 was added as it meets the intent of the policy.
2/2013	Annual review. Changes to policy statements. Effective 2/4/2013
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
12/2011	Annual review. Changes to policy statements.
11/2010	Reviewed - Medical Policy Group - Gastroenterology, Nutrition and Organ Transplantation. No changes to policy statements.
8/2010	Annual review. Changes to policy statements.
11/2009	Reviewed - Medical Policy Group - Gastroenterology, Nutrition and Organ Transplantation. No changes to policy statements.
11/2008	Reviewed - Medical Policy Group - Gastroenterology, Nutrition and Organ Transplantation. No changes to policy statements.

12/2008	New policy, effective 12/01/2008, describing covered and non-covered indications.
---------	---

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. *Gastroenterology*. Jun 1996; 110(6): 1982-96. PMID 8964428
2. Kessels SJM, Newton SS, Morona JK, et al. Safety and Efficacy of Wireless pH Monitoring in Patients Suspected of Gastroesophageal Reflux Disease: A Systematic Review. *J Clin Gastroenterol*. Oct 2017; 51(9): 777-788. PMID 28877081
3. Blue Cross and Blue Shield Assicaiton Technology Evaluation Center (TEC). Special Report: Wireless pH Monitoring. TEC Assessments. 2006;21(2).
4. Hakanson BS, Berggren P, Granqvist S, et al. Comparison of wireless 48-h (Bravo) versus traditional ambulatory 24-h esophageal pH monitoring. *Scand J Gastroenterol*. 2009; 44(3): 276-83. PMID 19040176
5. Wenner J, Johansson J, Johnsson F, et al. Optimal thresholds and discriminatory power of 48-h wireless esophageal pH monitoring in the diagnosis of GERD. *Am J Gastroenterol*. Sep 2007; 102(9): 1862-9. PMID 17509034
6. Schneider JH, Kramer KM, Konigsrainer A, et al. Ambulatory pH: monitoring with a wireless system. *Surg Endosc*. Nov 2007; 21(11): 2076-80. PMID 17484003
7. Grigolon A, Consonni D, Bravi I, et al. Diagnostic yield of 96-h wireless pH monitoring and usefulness in patients' management. *Scand J Gastroenterol*. May 2011; 46(5): 522-30. PMID 21366495
8. Sweis R, Fox M, Anggiansah A, et al. Prolonged, wireless pH-studies have a high diagnostic yield in patients with reflux symptoms and negative 24-h catheter-based pH-studies. *Neurogastroenterol Motil*. May 2011; 23(5): 419-26. PMID 21235685
9. Garrean CP, Zhang Q, Gonsalves N, et al. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy. *Am J Gastroenterol*. Jul 2008; 103(7): 1631-7. PMID 18557714
10. Scarpulla G, Camilleri S, Galante P, et al. The impact of prolonged pH measurements on the diagnosis of gastroesophageal reflux disease: 4-day wireless pH studies. *Am J Gastroenterol*. Dec 2007; 102(12): 2642-7. PMID 17850412
11. Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. *Clin Gastroenterol Hepatol*. Apr 2005; 3(4): 329-34. PMID 15822037
12. Bajbouj M, Becker V, Neuber M, et al. Combined pH-metry/impedance monitoring increases the diagnostic yield in patients with atypical gastroesophageal reflux symptoms. *Digestion*. 2007; 76(3-4): 223-8. PMID 18174685
13. Bredenoord AJ, Weusten BL, Timmer R, et al. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. *Am J Gastroenterol*. Mar 2006; 101(3): 453-9. PMID 16464226
14. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. *Gut*. Oct 2006; 55(10): 1398-402. PMID 16556669
15. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. *Gastroenterology*. Jun 2001; 120(7): 1599-606. PMID 11375942
16. Gyawali CP, Tutuian R, Zerbib F, et al. Value of pH Impedance Monitoring While on Twice-Daily Proton Pump Inhibitor Therapy to Identify Need for Escalation of Reflux Management. *Gastroenterology*. Nov 2021; 161(5): 1412-1422. PMID 34270955

17. Gyawali CP, Carlson DA, Chen JW, et al. ACG Clinical Guidelines: Clinical Use of Esophageal Physiologic Testing. *Am J Gastroenterol*. Sep 2020; 115(9): 1412-1428. PMID 32769426
18. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol*. Mar 2013; 108(3): 308-28; quiz 329. PMID 23419381
19. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. *Gastroenterology*. Oct 2008; 135(4): 1383-1391, 1391.e1-5. PMID 18789939
20. Vaezi MF, Pandolfino JE, Vela MF, et al. White Paper AGA: Optimal Strategies to Define and Diagnose Gastroesophageal Reflux Disease. *Clin Gastroenterol Hepatol*. Aug 2017; 15(8): 1162-1172. PMID 28344064
21. Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon Consensus. *Gut*. Jul 2018; 67(7): 1351-1362. PMID 29437910
22. Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis of gastroesophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. *Neurogastroenterol Motil*. Oct 2017; 29(10): 1-15. PMID 28370768
23. Savarino E, Bredenoord AJ, Fox M, et al. Expert consensus document: Advances in the physiological assessment and diagnosis of GERD. *Nat Rev Gastroenterol Hepatol*. Nov 2017; 14(11): 665-676. PMID 28951582
24. Richter JE, Pandolfino JE, Vela MF, et al. Utilization of wireless pH monitoring technologies: a summary of the proceedings from the esophageal diagnostic working group. *Dis Esophagus*. Nov-Dec 2013; 26(8): 755-65. PMID 22882487
25. Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. *J Pediatr Gastroenterol Nutr*. Mar 2018; 66(3): 516-554. PMID 29470322
26. National Institute for Health and Care Excellence (NICE). Catheterless esophageal pH monitoring [IPG187]. 2006; <https://www.nice.org.uk/Guidance/IPG187>. Accessed October 1, 2021.
27. National Institute for Health and Care Excellence (NICE). Gastro-oesophageal reflux disease in children and young people: diagnosis and management [NG1]. Updated October 9, 2019; <https://www.nice.org.uk/guidance/ng1>. Accessed October 1, 2021.